Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone585-271-2700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$720,000.00
Profitability
Miscellaneous
Employees44
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable
Vaccinex (NASDAQ:VCNX) Frequently Asked Questions
What is Vaccinex's stock symbol?
Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."
How were Vaccinex's earnings last quarter?
Vaccinex Inc (NASDAQ:VCNX) issued its earnings results on Tuesday, November, 12th. The company reported ($0.56) EPS for the quarter, topping the Zacks' consensus estimate of ($0.66) by $0.10. The business had revenue of $0.40 million for the quarter. Vaccinex had a negative net margin of 4,740.03% and a negative return on equity of 585.69%. View Vaccinex's Earnings History.
When is Vaccinex's next earnings date?
Has Vaccinex been receiving favorable news coverage?
Press coverage about VCNX stock has been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vaccinex earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Vaccinex.
Are investors shorting Vaccinex?
Vaccinex saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 105,200 shares, an increase of 23.6% from the December 15th total of 85,100 shares. Based on an average trading volume of 4,800 shares, the short-interest ratio is presently 21.9 days. Currently, 3.3% of the company's stock are sold short. View Vaccinex's Current Options Chain.
Who are some of Vaccinex's key competitors?
Some companies that are related to Vaccinex include Osmotica Pharmaceuticals (OSMT), BioXcel Therapeutics (BTAI), VBI Vaccines (VBIV), Avadel Pharmaceuticals (AVDL), Neptune Wellness Solutions (NEPT), IVERIC bio (ISEE), Geron (GERN), Evofem Biosciences (EVFM), Wave Life Sciences (WVE), Sol Gel Technologies (SLGL), Kamada (KMDA), MEI Pharma (MEIP), BIOFRONTERA AG/ADR (BFRA), Concert Pharmaceuticals (CNCE) and Advanz Pharma (CXRXF).
What other stocks do shareholders of Vaccinex own?
Who are Vaccinex's key executives?
Vaccinex's management team includes the folowing people:
- Dr. Maurice Zauderer, Co-Founder, CEO, Pres & Director (Age 73)
- Mr. Raymond E. Watkins, Sr. VP & COO (Age 61)
- Dr. Ernest S. Smith, Sr. VP of Research & Chief Scientific Officer (Age 47)
- Dr. Deepak M. Sahasrabudhe, Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
- Mr. Scott E. Royer C.F.A., M.B.A., Chief Financial Officer (Age 45)
When did Vaccinex IPO?
(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.
How do I buy shares of Vaccinex?
Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Vaccinex's stock price today?
One share of VCNX stock can currently be purchased for approximately $5.09.
How big of a company is Vaccinex?
Vaccinex has a market capitalization of $75.62 million and generates $720,000.00 in revenue each year. The company earns $-29,520,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Vaccinex employs 44 workers across the globe.View Additional Information About Vaccinex.
What is Vaccinex's official website?
How can I contact Vaccinex?
Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]
MarketBeat Community Rating for Vaccinex (NASDAQ VCNX)
MarketBeat's community ratings are surveys of what our community members think about Vaccinex and other stocks. Vote "Outperform" if you believe VCNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
